Loading clinical trials...
Loading clinical trials...
A Phase II, Open-Label, Multicenter Study of the Efficacy and Safety of Single-Agent PRO95780 in Patients With Advanced Chondrosarcoma
Conditions
Interventions
PRO95780
Locations
4
United States
Sarcoma Oncology Center
Santa Monica, California, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
MD Anderson Cancer Center
Houston, Texas, United States
Peter MacCallum Cancer Centre
Melbourne, Australia
Start Date
May 31, 2007
Primary Completion Date
May 5, 2008
Completion Date
May 5, 2008
Last Updated
December 13, 2022
NCT05039801
NCT06387485
NCT03449108
NCT05836571
NCT01449149
NCT06714773
Lead Sponsor
Genentech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions